Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCI

Celgene building

Celgene steps back from $1bn Sutro acquisition

Instead opts for amended licensing deal with US biotech

Celgene building

Celgene, Agios get FDA OK for leukaemia drug Idhifa

Duo’s drug becomes first new AML therapy since Novartis' Rydapt

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

Celgene building

Celgene joins PD-1 race via partnership with BeiGene

The pharma giant will pay the Chinese firm up to $980m in milestone payments

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.

Blue Latitude Health

Taking a hybrid qualitative-quantitative approach to research

Directors Phil Rosenberg and Chris Gaj discuss ways to achieve qualitative insights with quantitative precision and the benefits of a hybrid approach.Watch the video: https://www.researchpartnership.com/news/2017/06/video-taking-a-hybrid-qualitative-quantitative-appr...

Research Partnership

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership

- PMLiVE

Europe vs the US: New drug product approvals

As US approvals rates in the US drop,  the EU is not currently showing a similar trend

- PMLiVE

When science is not enough

Mundipharma’s Will Dunlop on a new framework to guide development programmes to a better destination

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

Polyphor appoints new chief medical and development officer

Dr Debra Baker joins the firm from Novartis

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links